Foamix Pharmaceuticals, Ltd.
2 Holzman Street
Weizmann-Science Park
Rehovot
76704
Tel: 972-8-9316233
Website: http://www.foamix.co.il/
115 articles with Foamix Pharmaceuticals, Ltd.
-
Although the U.S. FDA is very busy dealing with emergency use approvals for diagnostics and possible treatments for COVID-19, it is still evaluating and approving therapies for non-COVID-19 indications. Here’s a look at this week’s calendar.
-
Menlo Therapeutics and Cutia Therapeutics Enter into Exclusive License Agreement for AMZEEQ™ and Approved Topical Minocycline Products in Greater ChinaTransaction provides non-dilutive capital including $10M up-front
4/23/2020
Menlo Therapeutics Inc. announced that its wholly-owned subsidiary, Foamix Pharmaceuticals Ltd., has entered into a licensing agreement with specialty pharmaceutical company Cutia Therapeutics Limited, an affiliate of Cutia Therapeutics for AMZEEQ™ topical foam, 4% as well as its other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.
-
Menlo Announces Settlement to Conclude Finacea Foam Litigation and Announces that Partner, LEO Pharma A/S, Remedies Finacea Foam Supply Issues
4/2/2020
Menlo Therapeutics Inc. announced that its wholly-owned subsidiary, Foamix Pharmaceuticals Ltd. has entered into a settlement and license agreement to resolve the remaining pending patent litigation involving Finacea® Foam.
-
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
3/9/2020
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix”) following the satisfaction of all closing conditions required by the merger agreement.
-
Foamix Pharmaceuticals to Present at the Cowen and Company’s 40th Annual Health Care Conference
2/25/2020
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate update at the Cowen 40th Annual Health Care Conference, taking place March 2-4, 2020 in Boston, Massachusetts.
-
Clinical Catch-Up: February 17-21
2/24/2020
Mid-February had a solid number of clinical trial announcements. Here’s a look. -
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
2/18/2020
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced results from an integrated efficacy analysis on the two pivotal Phase 3 clinical trials for FMX103 (minocycline, 1.5% foam) currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe papulopustular rosacea in adults
-
Clinical Catch-Up: February 3-7, 2020
2/10/2020
Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look. -
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology
2/6/2020
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today the publication of the Company’s Phase 3 studies FX2016-11 and FX2016-12 (Studies 11 & 12) in the Journal of the American Academy of Dermatology (JAAD)
-
Foamix and Menlo Announce Shareholder Approval of Proposed MergerTransaction on Track to Close in early March 2020
2/6/2020
Foamix Pharmaceuticals Ltd. and Menlo Therapeutics Inc. announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and stockholder proposals necessary to complete the previously announced merger at their respective shareholder / stockholder meetings.
-
Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics
1/17/2020
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC (“OrbiMed”), a significant shareholder of the Company, intends to vote in favor of the proposed merger with Menlo Therapeutics at the Company’s upcoming extraordinary general meeting of shareholders
-
OrbiMed Supports the Proposed Foamix Pharmaceuticals Ltd. And Menlo Therapeutics Inc. Merger
1/16/2020
OrbiMed Advisors LLC (“OrbiMed”), on behalf of its clients, has evaluated the Joint Proxy Statement/Prospectus for the proposed merger of Foamix Pharmaceuticals Ltd. (“Foamix”) and Menlo Therapeutics Inc. (“Menlo”).
-
Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.
1/14/2020
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced a coverage update for its novel AMZEEQTM (minocycline) topical foam, 4%.
-
Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne
1/9/2020
AMZEEQ is the First FDA Approved Topical Form of Minocycline and the Company’s First Commercial Launch
-
Clinical Catch-Up: November 18-22
11/25/2019
As usual, it was a busy week for clinical trial updates. Here’s a look. -
Foamix Announces Enrollment Completion of Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam
11/18/2019
Foamix Pharmaceuticals Ltd., a specialty pharmaceutical company, announced the completion of Phase 2 clinical trial enrollment of FCD105 for the treatment of moderate-to-severe acne vulgaris.
-
Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/11/2019
Foamix Pharmaceuticals Ltd., a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced financial results for the three and nine months ended September 30, 2019 and provided a corporate update.
-
Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
11/11/2019
Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assets
-
The merged company will be led by David Domzalski, current chief executive officer of Foamix. It will be headquartered in New Jersey.
-
Foamix Announces Issuance of New U.S. Patent for Compositions Combining a Retinoid and a Tetracycline Antibiotic
11/7/2019
Foamix Pharmaceuticals Ltd., a specialty pharmaceutical company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,463,742, reciting waterless compositions comprising a retinoid and a tetracycline antibiotic, as well as methods of using those compositions in treating dermatological disorders.